4DMedical Limited (ASX: 4DX) announced that Cleveland Clinic has entered into a commercial arrangement to deploy its CT:VQ™ technology for clinical use. Widely regarded as one of the most respected healthcare institutions globally, Cleveland Clinic’s adoption represents a significant validation point for 4DMedical’s respiratory imaging platform.
Under the agreement, Cleveland Clinic will initially access CT:VQ™ under a one-month introductory pricing period designed to support integration into clinical workflows, before transitioning to full commercial terms. The structure aligns with 4DMedical’s broader commercialisation approach aimed at accelerating uptake within complex hospital environments.
Rapid Uptake Across Leading Medical Centres
The Cleveland Clinic deployment marks the third major United States academic medical centre to implement CT:VQ™ within just three months of the technology receiving regulatory clearance. Earlier adopters include Stanford University and the University of Miami, establishing a growing network of high-profile reference sites for the platform.
Management noted that adoption by leading academic medical centres is a deliberate strategy, with these institutions playing a key role in influencing broader clinical practice across national health systems. The company believes successful integration at such sites enhances visibility, credibility, and downstream adoption across community hospitals and regional networks.
Strengthening the Path to Standard of Care
CT:VQ™ combines ventilation and perfusion imaging using standard computed tomography scans, offering an alternative to traditional nuclear ventilation-perfusion imaging. 4DMedical believes the technology provides both clinical and operational advantages, including workflow efficiency and improved diagnostic insights, supporting its ambition to redefine respiratory imaging standards.
The Cleveland Clinic deployment is expected to serve as a flagship reference site, demonstrating the technology’s real-world clinical utility and reinforcing its positioning within the United States healthcare market.
Commercial Strategy and Partnerships
The company’s academic medical centre-focused rollout is complemented by strategic partnerships aimed at accelerating broader market penetration. Management highlighted the importance of these early deployments in building momentum following regulatory approval, particularly as 4DMedical works to scale adoption across diverse healthcare settings.
Leadership described the pace of uptake since clearance as encouraging, noting that early traction among elite institutions provides a strong foundation for ongoing commercial expansion.
Outlook
With CT:VQ™ now live at three prominent United States academic medical centres, 4DMedical continues to build momentum in its United States commercial rollout. Investor focus is likely to remain on the pace of further hospital adoption, conversion to full commercial contracts, and the broader impact of reference sites on system-wide uptake as the company advances its strategy to transform respiratory imaging care.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
4DMedical Expands U.S. Footprint as Cleveland Clinic Adopts CT:VQ™
Highlights:
Cleveland Clinic Adoption Signals Commercial Momentum
4DMedical Limited (ASX: 4DX) announced that Cleveland Clinic has entered into a commercial arrangement to deploy its CT:VQ™ technology for clinical use. Widely regarded as one of the most respected healthcare institutions globally, Cleveland Clinic’s adoption represents a significant validation point for 4DMedical’s respiratory imaging platform.
Under the agreement, Cleveland Clinic will initially access CT:VQ™ under a one-month introductory pricing period designed to support integration into clinical workflows, before transitioning to full commercial terms. The structure aligns with 4DMedical’s broader commercialisation approach aimed at accelerating uptake within complex hospital environments.
Rapid Uptake Across Leading Medical Centres
The Cleveland Clinic deployment marks the third major United States academic medical centre to implement CT:VQ™ within just three months of the technology receiving regulatory clearance. Earlier adopters include Stanford University and the University of Miami, establishing a growing network of high-profile reference sites for the platform.
Management noted that adoption by leading academic medical centres is a deliberate strategy, with these institutions playing a key role in influencing broader clinical practice across national health systems. The company believes successful integration at such sites enhances visibility, credibility, and downstream adoption across community hospitals and regional networks.
Strengthening the Path to Standard of Care
CT:VQ™ combines ventilation and perfusion imaging using standard computed tomography scans, offering an alternative to traditional nuclear ventilation-perfusion imaging. 4DMedical believes the technology provides both clinical and operational advantages, including workflow efficiency and improved diagnostic insights, supporting its ambition to redefine respiratory imaging standards.
The Cleveland Clinic deployment is expected to serve as a flagship reference site, demonstrating the technology’s real-world clinical utility and reinforcing its positioning within the United States healthcare market.
Commercial Strategy and Partnerships
The company’s academic medical centre-focused rollout is complemented by strategic partnerships aimed at accelerating broader market penetration. Management highlighted the importance of these early deployments in building momentum following regulatory approval, particularly as 4DMedical works to scale adoption across diverse healthcare settings.
Leadership described the pace of uptake since clearance as encouraging, noting that early traction among elite institutions provides a strong foundation for ongoing commercial expansion.
Outlook
With CT:VQ™ now live at three prominent United States academic medical centres, 4DMedical continues to build momentum in its United States commercial rollout. Investor focus is likely to remain on the pace of further hospital adoption, conversion to full commercial contracts, and the broader impact of reference sites on system-wide uptake as the company advances its strategy to transform respiratory imaging care.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au